BioWorld

June 23, 2006

View Archived Issues

SuperGen's $34M Sell-Off To Mayne Includes Nipent

In an effort to focus on its preclinical targeted therapeutics, SuperGen Inc. decided to sell the North American rights to Nipent and SurfaceSafe to Mayne Pharma Ltd. in a deal worth $34 million. (BioWorld Today) Read More

XenoPort Offering: $76.5M For Transported Prodrugs

Read More

Supreme Court's Non-Ruling Seen As Friendly To Biotech

Read More

QuatRx Adds HSD Inhibitors To Endocrine Drug Pipeline

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More